Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis
AssigneeCaritas St.Elizabeth Medical Center of Boston, Inc
InventorDouglas W. Losordo
Life of this patent
Estimating the term…
Abstract
The present invention generally provides methods for preventing, treating or reducing the severity of symptoms associated with tissue ischemia by administering a CXCR4 antagonist in combination with at least one nucleic acid encoding a morphogen or effective fragment thereof. In one embodiment, the methods include elevating peripheral blood endothelial progenitor cells (EPCs), bone marrow-derived stem cells (BMSCs), or both cell types. The invention has a wide spectrum of applications including reducing or eliminating tissue ischemia, especially tissue ischemia associated with a myocardial infarct (heart attack).
Claims29
A method of preventing, treating, and/or alleviating symptoms associated with tissue ischemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of (a) at least one CXCR4 antagonist and (b) at least one nucleic acid encoding at least one morphogen or an effective fragment of a morphogen, to prevent, treat, or alleviate the symptoms associated with the tissue ischemia in the subject.
2-14. (canceled)
24-26. (canceled)
28-35. (canceled)
A method for inducing new blood vessel growth in myocardial tissue of a mammal in need of such treatment comprising administering a therapeutically effective amount of (a) at least one CXCR4 antagonist;
- and (b) at least one nucleic acid encoding at least one morphogen or an effective fragment of a morphogen.
(canceled)
41-44. (canceled)
A pharmaceutical product for preventing, alleviating, or treating an ischemic disorder in a mammal, the product comprising (a) at least one CXCR4 antagonist;
- and (b) at least one nucleic acid encoding at least one morphogen, or at least one nucleic acid encoding at least an effective fragment of a morphogen, wherein each the antagonist and the nucleic acid are formulated to be physiologically acceptable to a mammal, the product further comprising means for administering the product to the mammal.
46-47. (canceled)
49-50. (canceled)
A method for increasing production of EPCs and/or BMSCs in a subject, the method comprising administering a therapeutically effective amount of at least one of a CXCR4 antagonist and a nucleic acid encoding at least one of an N-terminal portion of human hedgehog (SHh) protein, human desert hedgehog (DHh) protein or human Indian Hedgehog (IHh) protein;
- the method further comprising increasing presence of the EPCs and/or the BMSCs in the subject.
(canceled)
A use of a composition for preparation of a medicament for preventing, treating, and/or alleviating symptoms associated with tissue ischemia, the composition comprising a therapeutically effective amount of (a) at least one CXCR4 antagonist;
- and (b) at least one nucleic acid encoding at least one morphogen or an effective fragment of a morphogen.
(canceled)
Dependencies are inferred from the claim text.